Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase 1/2 2

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

HR+/HER2- Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 49fludarabine 37Injections 32Gemcitabine 24Paclitaxel 23Cisplatin 21pembrolizumab 19Radiotherapy 19toripalimab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 13Nivolumab 12Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Cetuximab 11Bevacizumab 10Irinotecan 9Immunotherapy, Adoptive 9Drug Therapy 9Etoposide 8sintilimab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7Leucovorin 7Ipilimumab 7Indium 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Unknown × dalpiciclib × Clear all
NCT06225921 2024-03-06

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

West China Hospital

Phase 1 Unknown
6 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05515289 2023-03-10

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
30 enrolled
Breast

Breast Neoplasms

NCT05586841 2022-10-19

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Unknown
30 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡